2019, Chemotherapy and Vaccines - Pharmacy Technician Pulse

2019

Chemotherapy

Vaccines

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

JUNE 27, 2025

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Pharmacists are well positioned to perform drug interaction checks, counsel patients on adherence and administration, and coordinate supportive care, including prophylaxis for infections (eg, granulocyte colony-stimulating factor, vaccines).

FDA

FDA Compounding Pharmacies Immunization Chemotherapy

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

JUNE 20, 2025

December 12, 2019. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development. Updated January 19, 2024. Accessed May 15, 2025. LinkedIn Workplace Learning Report 2024. LinkedIn Learning. Accessed May 15, 2025.

Compounding

Compounding Compounding Pharmacies Patient Care Immunization

Join 5,000+

Insiders

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

J&J eyes prostate cancer label expansion for Akeega

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out? Find out more J&J’s drug is an option for patients where medical or surgical treatment to lower testosterone levels has not worked, and in those who have BRCA 1/2 mutations – a subset of homologous recombination repair (HRR) mutations – in whom chemotherapy is not indicated.

Labelling

Labelling Packaging Communication Hospitals

Personalising peptide vaccines for treating glioblastoma: expert pharmacist commentary

Hospital Pharmacy Europe

OCTOBER 2, 2024

Pharmacist Dr João Gonçalves PhD considers the real-world evidence of a recent study demonstrating the feasibility and efficacy of a personalised peptide vaccine for glioblastoma – one of the most malignant primary brain tumours in adults.

Vaccines

Vaccines Immunization Chemotherapy Hospitals

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

SEPTEMBER 8, 2020

In England for instance, the introduction of a biosimilar to prevent neutropenia in patients undergoing chemotherapy, resulted in a number of Strategic Health Authorities reassessing their guidance relating to this medicine. Published 8 March 2019. Published 25 November 2019. Published 17 September 2018. Available from: [link].

Chemotherapy

Chemotherapy Patient Care Vaccines FDA

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

DECEMBER 12, 2023

IPH5201 is being investigated in a Phase II trial, MATISSE, in combination with durvalumab (anti-PD-L1) and chemotherapy, in patients with resectable early-stage NSCLC. Innate Pharma also developing IPH5201 in collaboration with AstraZeneca. percent, reaching even 57.1 percent in the skin.

Immunization

Immunization Chemotherapy Pharmaceutical Companies Pharmaceutical Companies

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

pharmaphorum

APRIL 7, 2021

Under the leadership of CEO Jan van de Winkel it has gone from financially precarious position following the stock market crash in the late noughties, to the darling of the Nasdaq with a US IPO of more than $500 million in 2019. There’s potential for combination drugs, paving the way for less toxic chemotherapy-free cancer drugs.

Chemotherapy

Chemotherapy Hospitals Vaccines

Pembrolizumab by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Pharmaceutical Technology

MARCH 2, 2023

Keytruda is indicated in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. It is also indicated for the treatment of metastatic transitional (urothelial) tract cancer and gastric cancer.

Chemotherapy

Chemotherapy FDA Vaccines Immunization

Health Innovation Fund, Moderna’s largest shareholder, shares investment strategies

pharmaphorum

AUGUST 22, 2022

Chemotherapy, the current standard of care for cancer treatment, can be harmful to both the cancer cells and the body’s healthy cells. ” Moderna has also created a personalised cancer vaccine, a similar idea where the vaccine is built against the specific cancer one has in the body. ” About the interviewee.

Vaccines

Vaccines Chemotherapy Immunization

What causes sharp pain on the right side of the body?

The Checkup by Singlecare

NOVEMBER 13, 2023

According to the CDC , treatment includes surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these treatments. To help decrease the risk of shingles, Shingrix vaccine is FDA-approved for adults 50 and older. It is a two-vaccine series and significantly decreases the risk of a shingles outbreak.

Mayo Clinic

Mayo Clinic Vaccines Chemotherapy Communication

Governments and pharma relationships and implications for antimicrobial resistance

Pharmaceutical Technology

AUGUST 1, 2022

Since 2020, government agencies have provided funding for expensive late-stage vaccine development and the expansion of manufacturing capacity, as well as other key pharmaceutical activities. The shift from private to public funding enabled more rapid development of Covid-19 drugs and vaccines.

Vaccines

Vaccines Pharmaceutical Companies Pharmaceutical Companies Chemotherapy

ESMO 2022: data updates push immunotherapy’s scope in cervical cancer

Pharmaceutical Technology

SEPTEMBER 14, 2022

Early-stage cervical cancer patients achieve good recovery through surgery and concurrent chemotherapy, but treatment options are scarce for those with recurrent metastatic cervical cancer. months, following an ESMO 2019 presentation on data from the same study. Phase I/II Checkmate-358 trial. After a median follow-up of 30.2

Chemotherapy

Chemotherapy Vaccines Dosage FDA

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT

MARCH 6, 2023

Still, when doctors told her last year that the cancer was growing despite two operations, radiation therapy, and a fifth regimen of chemotherapy, the retired business-meeting facilitator decided to do something unorthodox: spend $83,000 out of pocket on an unproven experimental cancer vaccine.

Vaccines

Vaccines FDA Immunization Chemotherapy

Cancer statistics 2023

The Checkup by Singlecare

AUGUST 3, 2023

NCI , 2023) Between 1999 and 2019, cancer accounted for more than one million deaths among Black men and women ages 20 years and older. ( NIH , 2022) Between 1999 and 2019, there was an annual decrease of 2% in the number of cancer death rates among Black men and women. ( In 2019, patients paid $16.22 ACS , 2023). had to pay $5.6

Chemotherapy

Chemotherapy Hospitals Insurance Immunization

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Trending Sources

J&J eyes prostate cancer label expansion for Akeega

Personalising peptide vaccines for treating glioblastoma: expert pharmacist commentary

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

NK cell immunotherapy: what’s next in clinical development?

Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab

Pembrolizumab by Merck for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Health Innovation Fund, Moderna’s largest shareholder, shares investment strategies

What causes sharp pain on the right side of the body?

Governments and pharma relationships and implications for antimicrobial resistance

ESMO 2022: data updates push immunotherapy’s scope in cervical cancer

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

Cancer statistics 2023

Stay Connected